UniProt P51955 · PDB · AlphaFold · Substrate: MBP · Clone: full-lengthmedium-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Neratinib | 91.1% | 8.9% | 93.18 | 0.597 |
| 2 | Infigratinib | 51.0% | 49.0% | 98.24 | 0.710 |
| 3 | Vemurafenib | 48.1% | 51.9% | 96.49 | 0.598 |
| 4 | Gilteritinib | 47.4% | 52.6% | 88.97 | 0.506 |
| 5 | Bosutinib | 46.1% | 53.9% | 87.22 | 0.555 |
| 6 | Pazopanib | 42.6% | 57.4% | 97.49 | 0.672 |
| 7 | Sunitinib | 22.0% | 78.0% | 91.73 | 0.524 |
| 8 | Tivozanib | 17.2% | 82.8% | 92.42 | 0.673 |
| 9 | Dabrafenib | 17.2% | 82.8% | 94.74 | 0.633 |
| 10 | Ripretinib | 13.7% | 86.3% | 92.95 | 0.674 |
| 11 | Fostamatinib | 13.3% | 86.7% | 96.74 | 0.613 |
| 12 | Tofacitinib | 11.4% | 88.6% | 99.25 | 0.684 |
| 13 | Dacomitinib | 11.3% | 88.7% | 97.99 | 0.664 |
| 14 | Defactinib | 10.5% | 89.5% | 92.68 | 0.450 |
| 15 | Ibrutinib | 10.3% | 89.7% | 94.74 | 0.723 |
| 16 | Pirtobrutinib | 9.6% | 90.4% | 99.49 | 0.656 |
| 17 | Dasatinib | 9.4% | 90.6% | 87.97 | 0.699 |
| 18 | Afatinib | 9.1% | 90.9% | 98.50 | 0.709 |
| 19 | Duvelisib | 8.7% | 91.3% | 100.00 | 0.716 |
| 20 | Selumetinib | 8.5% | 91.5% | 100.00 | 0.640 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.63
- Epithelial log2(TPM+1): 4.94
- Fold change: -0.31
- Status: No significant change
High-confidence drugs
- Neratinib — inh 91.1% · KISS 31.63
- Infigratinib — inh 51.0% · KISS -1.11
- Vemurafenib — inh 48.1% · KISS -13.58
Selectivity landscape vs inhibition on NEK2
Each point is one of the 92 approved drugs; color = inhibition % on NEK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…